Огляд
Select a topic to solve related cases or follow a course topic
-
Topic 1Finding the right ADT for the right patient
-
Topic 2Adjuvant therapy in RCC
-
Topic 3Finding the right ADT for the right patient
-
Topic 4Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 5High-risk non-metastatic prostate cancer
-
Topic 6Personalising care for patients with biochemical recurrence
-
Topic 7Sequencing treatments in mCRPC patients without HRR gene mutations
-
Topic 8Treatment selection in mCRPC patients harbouring HRR gene mutations
-
Topic 9Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 10Low- and intermediate-risk NMIBC: surveillance or intravesical therapy?
-
Topic 11Management of neurofibromatosis type 1
-
Topic 12CDK4/6 inhibitors for everyone? First-line treatment strategies in HR+ HER2- MBC
-
Topic 13Progression after CDK4/6i + ET for HR+ HER2- MBC. What now?
-
Topic 14First-line therapy of synchronous and metachronous metastatic UCa
-
Topic 15Adjuvant treatment approaches for MIBC
-
Topic 16Initial treatment of MIBC
-
Topic 17Management of BCG-pretreated (very) high-risk NMIBC
-
Topic 18Treatment approaches for patients diagnosed with (very) high-risk NMIBC
-
Topic 19New hope for patients progressing after prior treatment for mUCa
-
Topic 20Managing adverse events of systemic therapies in muscle-invasive and metastatic UCa
-
Topic 21Follow-up surveillance regimens to consider for (very) high-risk NMIBC and MIBC
-
Topic 22Follow-up surveillance regimes for low-/intermediate-risk NMIBC
-
Topic 23First-line systemic therapy in metastatic renal cell carcinoma
-
Topic 24Systemic therapy for mRCC: second line and beyond
-
Topic 25Management of small renal masses
-
Topic 26Local therapy for mRCC